<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="neurology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">248</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2023.31232</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropathic Pain Management, Pharmacological Approaches, Neuromodulation and Quality of Life
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>Bayan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alqubaishi</surname>
<given-names>Reem</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Asiri</surname>
<given-names>Fahad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkhadhrawi</surname>
<given-names>Mohammed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aldhohayan</surname>
<given-names>Alhanouf</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aljabri</surname>
<given-names>Faisal</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alahmari</surname>
<given-names>Abdullah</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alharbi</surname>
<given-names>Rahaf</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Altowairqi</surname>
<given-names>Meshal</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshawaf</surname>
<given-names>Raed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alzahrani</surname>
<given-names>Khalid</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>28</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>3</volume>
<issue>12</issue>
<fpage>777</fpage>
<lpage>788</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Neuropathic pain, which affects 7%–10% of the general population, is caused by a lesion or disease of the somatosensory system, which includes peripheral fibers and central neurons. There are numerous known causes of neuropathic pain, and as the world__ampersandsign#39;s population ages, the prevalence of diabetes mellitus rises, and cancer patients are more likely to survive post-chemotherapy. Its occurrence is projected to rise. The intricacy of neuropathic symptoms, adverse outcomes, and challenging treatment choices all appear to contribute to the burden of chronic neuropathic pain. Crucially, neuropathic pain patients have a lower quality of life due to a higher need for prescription drugs, more frequent visits to the physician, the morbidity from the pain itself, and the underlying disease. The most effective strategy to treat neuropathic pain would employ the right combination of pharmacological and nonpharmacologic therapy. As first-line treatments, gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are advised while tramadol and opioids are regarded as second-line therapy. Because there are currently insufficient high-quality trials, cannabinoids are advised as third-line treatments, and methadone and some anticonvulsants are suggested as fourth-line therapies. In cases of failure of pharmacological therapy or other special considerations, neuromodulation therapy is suggested, which involves deep brain stimulation, spinal cord stimulation, transcranial magnetic stimulation, and transcranial current stimulation and is broadly categorized under invasive and non-invasive neuromodulation procedures. In this study, we aim to comprehensively review the existing management strategies for neuropathic pain, specifically in the context of pharmacological, neuromodulation, and quality of life domains.
</p>
</abstract>
<kwd-group>
<kwd>neuropathic</kwd>
<kwd> pain</kwd>
<kwd> pharmacological</kwd>
<kwd> therapy</kwd>
<kwd> quality of life</kwd>
</kwd-group>
</article-meta>
</front>
</article>